Viral RNA N6-methyladenosine modification modulates both innate and adaptive immune responses of human respiratory syncytial virus
Creators
- 1. Ohio State University
- 2. Harvard University
- 3. University of Chicago
- 4. Nationwide Children's Hospital
Description
Human respiratory syncytial virus (RSV) is the leading cause of respiratory tract infections in humans. A well-known challenge in the development of a live attenuated RSV vaccine is that interferon (IFN)-mediated antiviral responses are strongly suppressed by RSV nonstructural proteins which, in turn, dampens the subsequent adaptive immune responses. Here, we discovered a novel strategy to enhance innate and adaptive immunity to RSV infection. Specifically, we found that recombinant RSVs deficient in viral RNA N6-methyladenosine (m6A) and RSV grown in m6A methyltransferase (METTL3)-knockdown cells induce higher expression of RIG-I, bind more efficiently to RIG-I, and enhance RIG-I ubiquitination and IRF3 phosphorylation compared to wild-type virion RNA, leading to enhanced type I IFN production. Importantly, these m6A-deficient RSV mutants also induce a stronger IFN response in vivo, are significantly attenuated, induce higher neutralizing antibody and T cell immune responses in mice and provide complete protection against RSV challenge in cotton rats. Collectively, our results demonstrate that inhibition of RSV RNA m6A methylation enhances innate immune responses which in turn promote adaptive immunity.
Data availability
All relevant data are within the manuscript and its Supporting Information files.Files
journal.ppat.1010142.pdf
Additional details
Identifiers
- DOI
- 10.1371/journal.ppat.1010142
- Other
- oai:uchicago.tind.io:5892
Funding
- National Institutes of Health
- R01 AI090060
- National Institutes of Health
- P01 AI112524
- National Institutes of Health
- R00 AI125136
- National Institutes of Health
- R01AI111784
- National Institutes of Health
- RM1 HG008935
- National Institutes of Health
- AI090060